


Imirestat

Cat. No.:	HY-16255		
CAS No.:	89391-50-4		
Molecular Formula:	C ₁₅ H ₈ F ₂ N ₂ O ₂		
Molecular Weight:	286.23		
Target:	Aldose Reductase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (291.13 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.4937 mL	17.4685 mL	34.9369 mL
		5 mM	0.6987 mL	3.4937 mL	6.9874 mL
10 mM		0.3494 mL	1.7468 mL	3.4937 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
In Vivo	<p>Imirestat (1 mg/kg) improves nerve conduction velocity but is without effect upon the resistance to hypoxic conduction blockade or the deficit in insulin-stimulated ouabain-sensitive ATPase activity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

-
- bioRxiv. 2023 Apr 9.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Carrington AL, et al. Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na⁺/K⁺-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia. 1991 Jun;34(6):397-401.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA